Kenji Ikeda

Author PubWeight™ 252.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006 10.69
2 Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008 9.20
3 Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013 5.03
4 Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009 3.77
5 Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012 3.54
6 Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010 3.00
7 Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 2.83
8 Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013 2.36
9 Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2012 2.34
10 Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2012 2.14
11 Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011 2.09
12 Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2006 2.09
13 Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009 1.83
14 Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008 1.76
15 Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005 1.71
16 Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci 2008 1.67
17 Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004 1.66
18 Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol 2008 1.59
19 Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol 2012 1.53
20 Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol 2004 1.46
21 Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol 2002 1.45
22 Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J Gastroenterol 2003 1.45
23 Global democratic consensus on neuropathological disease criteria. Lancet Neurol 2002 1.44
24 Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol 2002 1.43
25 Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol 2004 1.42
26 Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. J Gastroenterol 2004 1.41
27 Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012 1.35
28 Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2005 1.26
29 Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2011 1.21
30 Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007 1.16
31 Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 2004 1.13
32 Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke 2003 1.13
33 Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011 1.12
34 Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain. Acta Neuropathol 2003 1.10
35 Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007 1.10
36 Enhanced expression of aquaporin 4 in human brain with infarction. Acta Neuropathol 2003 1.09
37 Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res 2012 1.07
38 Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. J Gastroenterol 2002 1.06
39 The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 2003 1.05
40 Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. Neuropathology 2010 1.04
41 Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006 1.04
42 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathol 2004 1.01
43 Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007 1.00
44 Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol 2013 1.00
45 Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog Neuropsychopharmacol Biol Psychiatry 2003 1.00
46 Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. J Med Virol 2002 0.99
47 Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 2007 0.99
48 Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir. J Clin Virol 2009 0.99
49 High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009 0.99
50 Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol 2014 0.98
51 Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005 0.98
52 Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007 0.98
53 A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol 2009 0.97
54 Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 2006 0.97
55 YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol 2004 0.97
56 The influence of histological differentiation grade on the outcome of liver resection for hepatocellular carcinomas 2 cm or smaller in size. World J Surg 2015 0.96
57 Activation of vascular endothelial cells and perivascular cells by systemic inflammation-an immunohistochemical study of postmortem human brain tissues. Acta Neuropathol 2004 0.96
58 Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006 0.96
59 Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil. Intervirology 2009 0.96
60 Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med 2008 0.96
61 An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads. Intervirology 2009 0.95
62 Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J Gastroenterol 2004 0.95
63 Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007 0.94
64 Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol 2012 0.94
65 Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. J Med Virol 2013 0.94
66 Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol 2002 0.94
67 Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011 0.93
68 Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol 2010 0.93
69 Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005 0.92
70 Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 2012 0.92
71 Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up. J Med Virol 2005 0.91
72 Change of hepatitis B virus genotypes in acute and chronic infections in Japan. J Med Virol 2008 0.91
73 Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006 0.91
74 Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res 2009 0.91
75 Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol 2012 0.91
76 Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. J Clin Microbiol 2013 0.91
77 Protective effects of lactoferrin against intestinal mucosal damage induced by lipopolysaccharide in human intestinal Caco-2 cells. Yakugaku Zasshi 2008 0.90
78 A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther 2014 0.90
79 Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection. J Gastroenterol 2004 0.90
80 Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Intervirology 2009 0.90
81 Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 2002 0.90
82 Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol 2010 0.90
83 Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma. Oncology 2002 0.90
84 Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus. J Gastroenterol 2008 0.89
85 Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol 2011 0.89
86 Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers. J Gastroenterol 2012 0.89
87 Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009 0.89
88 Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy. J Med Virol 2003 0.89
89 Two distinct subgroups of senile dementia of Alzheimer type: quantitative study of neurofibrillary tangles. Neuropathology 2003 0.88
90 Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 2009 0.88
91 Glial involvement in diffuse Lewy body disease. Acta Neuropathol 2002 0.88
92 Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol 2005 0.88
93 Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol 2007 0.88
94 Neuronal and glial inclusions in frontotemporal dementia with or without motor neuron disease are immunopositive for p62. Neurosci Lett 2003 0.88
95 Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology 2012 0.88
96 Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol 2012 0.87
97 Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gastroenterol 2005 0.87
98 Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 2003 0.87
99 Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report. Hepatol Res 2007 0.86
100 Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 2009 0.86
101 Sporadic amyotrophic lateral sclerosis of long duration mimicking spinal progressive muscular atrophy exists: additional autopsy case with a clinical course of 19 years. Neuropathology 2004 0.86
102 Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clin Oncol 2011 0.86
103 Changes of the peptide YY levels in the intestinal tissue of rats with experimental colitis following oral administration of mesalazine and prednisolone. Yakugaku Zasshi 2008 0.86
104 Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int 2008 0.86
105 Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007 0.86
106 Sporadic amyotrophic lateral sclerosis with circumscribed temporal atrophy: a report of an autopsy case without dementia and with ubiquitinated intraneuronal inclusions. Neuropathology 2002 0.86
107 Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2007 0.86
108 Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology 2011 0.86
109 Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. Intern Med 2013 0.86
110 Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. J Gastroenterol 2012 0.86
111 Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol 2012 0.86
112 Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 2011 0.86
113 Minimum resection margin should be based on tumor size in hepatectomy for hepatocellular carcinoma in hepatoviral infection patients. Hepatol Res 2013 0.85
114 Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. Intervirology 2012 0.85
115 Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. Hepatol Res 2009 0.85
116 Coexistence of CJD and Alzheimer's disease: an autopsy case showing typical clinical features of CJD. Neuropathology 2004 0.85
117 Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b. J Med Virol 2014 0.85
118 Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 2010 0.85
119 Pick body disease and Pick syndrome. Neuropathology 2003 0.85
120 HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010 0.85
121 Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res 2012 0.84
122 Microglial tau undergoes phosphorylation-independent modification after ischemia. Glia 2004 0.84
123 Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. J Med Virol 2008 0.84
124 An autopsy case of Creutzfeldt-Jakob disease with a V180I mutation of the PrP gene and Alzheimer-type pathology. Neuropathology 2009 0.84
125 Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res 2013 0.84
126 Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 2008 0.84
127 Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection. Intervirology 2004 0.83
128 Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 2009 0.83
129 Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load. Hepatol Res 2003 0.83
130 Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J Med Virol 2006 0.83
131 Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology 2011 0.83
132 Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol 2008 0.83
133 Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome. J Gastroenterol Hepatol 2004 0.83
134 Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2003 0.83
135 Precore wild-type hepatitis B virus with G1896 in the resolution of persistent hepatitis B virus infection. Intervirology 2003 0.83
136 Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL. Hepatol Res 2012 0.82
137 Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 2002 0.82
138 Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions. Acta Neuropathol 2004 0.82
139 Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy. J Med Virol 2003 0.82
140 Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study. Hepatol Res 2014 0.82
141 Effects of capsaicin on cellular damage and monolayer permeability in human intestinal Caco-2 cells. Biol Pharm Bull 2007 0.82
142 Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol 2010 0.82
143 Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection. Intervirology 2004 0.81
144 Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2004 0.81
145 Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J Med Virol 2010 0.81
146 Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation. AJR Am J Roentgenol 2011 0.81
147 Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. J Med Virol 2004 0.81
148 Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Intern Med 2007 0.81
149 Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol 2013 0.81
150 Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res 2011 0.81
151 A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. Intern Med 2003 0.81
152 Factors associated with early cancer-related death after curative hepatectomy for solitary small hepatocellular carcinoma without macroscopic vascular invasion. J Hepatobiliary Pancreat Sci 2013 0.81
153 NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC). Acta Neuropathol 2002 0.81
154 Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med 2010 0.81
155 Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 2006 0.80
156 Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study. J Hepatol 2003 0.80
157 Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. J Clin Microbiol 2013 0.80
158 Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients. Hepatol Res 2014 0.80
159 Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004 0.80
160 Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. Hepatol Res 2013 0.80
161 Investigation of cellular metallic elements in single neurons of human brain tissues. Neuroreport 2002 0.80
162 Effects of aging on the morphologies of Heschl's gyrus and the superior temporal gyrus in schizophrenia: a postmortem study. Schizophr Res 2011 0.80
163 Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. J Med Virol 2006 0.80
164 Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology 2007 0.80
165 Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. J Med Virol 2012 0.80
166 Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load. Intervirology 2004 0.80
167 Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load. Hepatol Res 2012 0.80
168 Immunohistochemical study of the serotonergic neuronal system in an animal model of the mood disorder. Exp Neurol 2006 0.80
169 Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol 2014 0.80
170 Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma. Oncology 2016 0.80
171 Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C. J Med Virol 2013 0.80
172 Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. Oncology 2016 0.79
173 The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease. Intern Med 2011 0.79
174 Tau-positive fine granules in the cerebral white matter: a novel finding among the tauopathies exclusive to parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 2005 0.79
175 In hepatocellular carcinomas, any proportion of poorly differentiated components is associated with poor prognosis after hepatectomy. World J Surg 2014 0.79
176 Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis. J Gastroenterol 2004 0.79
177 Transarterial embolization with use of lipiodol and gelatin sponge for active nasal bleeding from hepatocellular carcinoma metastasis in the pituitary gland. Neurol Med Chir (Tokyo) 2011 0.79
178 Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005 0.79
179 Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection. J Gastroenterol 2007 0.79
180 [An autopsy case of "progressive supranuclear palsy" without psychiatric or neurological signs]. No To Shinkei 2004 0.79
181 Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol 2007 0.79
182 Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment. Intervirology 2005 0.79
183 Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res 2011 0.79
184 Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases. Intervirology 2010 0.79
185 Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intern Med 2008 0.78
186 Basal ganglia lesions in 'Pick complex': a topographic neuropathological study of 19 autopsy cases. Neuropathology 2002 0.78
187 Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2006 0.78
188 Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. Intern Med 2011 0.78
189 An atypical autopsy case of Lewy body disease with clinically diagnosed major depression: a clinical, radiological and pathological study. Neuropathology 2008 0.78
190 HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy. Liver Int 2014 0.78
191 Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. J Med Virol 2006 0.78
192 Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load. Intern Med 2010 0.78
193 Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients. J Gastroenterol 2008 0.78
194 New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma. Hepatol Res 2010 0.78
195 Tau accumulation in the nucleus accumbens in tangle-predominant dementia. Acta Neuropathol Commun 2014 0.78
196 Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C. Intervirology 2008 0.78
197 Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol 2013 0.78
198 Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases. Gut Liver 2013 0.78
199 Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. Hepatol Res 2007 0.78
200 Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol 2009 0.78
201 Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. J Med Virol 2008 0.78
202 The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load. Intern Med 2008 0.78
203 Morphological, molecular and developmental characterization of the thelastomatid nematode Thelastoma bulhoesi (de Magalhães, 1900) (Oxyuridomorpha: Thelastomatidae) parasite of Periplaneta americana (Linnaeus, 1758) (Blattodea: Blattidae) in Japan. Acta Parasitol 2016 0.78
204 Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia. Acta Neuropathol 2004 0.78
205 Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology 2003 0.77
206 The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2. Intern Med 2009 0.77
207 [Argyrophilic grain disease clinically mimicking Parkinson's disease with dementia: report of an autopsy case]. No To Shinkei 2004 0.77
208 Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007 0.77
209 Prolonged hepatitis after acute infection with genotype H hepatitis B virus. Intern Med 2007 0.77
210 Randomized Controlled Trial Comparing the Efficacy of Impedance Control and Temperature Control of Radiofrequency Interstitial Thermal Ablation for Treating Small Hepatocellular Carcinoma. Oncology 2015 0.77
211 Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis. J Med Virol 2005 0.77
212 Clinical features of hepatitis B virus genotype A in Japanese patients. J Gastroenterol 2003 0.77
213 Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy. J Gastroenterol 2004 0.77
214 Ubiquitin and ubiquitin-related proteins in the brains of patients with atypical Pick's disease without Pick bodies and dementia with motor neuron disease. Neuropathology 2004 0.77
215 Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. Clin Drug Investig 2012 0.77
216 Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment. Intervirology 2009 0.77
217 Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease. J Med Virol 2008 0.77
218 The distribution of serotonin transporter immunoreactivity in hippocampal formation in monkeys and rats. Brain Res 2004 0.77
219 Correlation between plasma glucagon-like peptide 2 levels and proliferative makers in small intestinal injury in rats induced by methotrexate administration. Biol Pharm Bull 2006 0.77
220 Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load. Hepatol Res 2012 0.77
221 Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses. Hepatol Res 2008 0.77
222 Preservation of nigral neurons in Pick's disease with Pick bodies: a clinicopathological and morphometric study of five autopsy cases. J Neurol Sci 2002 0.77
223 Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients. Hepatol Res 2002 0.77
224 Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B. J Gastroenterol Hepatol 2005 0.77
225 Postmortem analyses of drugs in pericardial fluid and bone marrow aspirate. J Anal Toxicol 2013 0.76
226 Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral liver disease. Hepatol Res 2013 0.76
227 Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load. Intern Med 2009 0.76
228 Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. J Gastroenterol 2003 0.76
229 [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin]. Gan To Kagaku Ryoho 2010 0.76
230 Immunolocalization of 14-3-3 isoforms in brains with Pick body disease. Neurosci Lett 2004 0.76
231 Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. J Gastroenterol 2013 0.76
232 Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment. Hepatol Res 2009 0.76
233 Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis. Dig Dis Sci 2010 0.76
234 What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study. Gut Liver 2013 0.76
235 The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load. Intern Med 2008 0.76
236 Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma--direct ablative effects and a long-term outcome. Liver Int 2007 0.76
237 Parkinson's disease mimicking senile dementia of the Alzheimer type: a clinicopathological study of four autopsy cases. Neuropathology 2002 0.76
238 Usefulness of the serum KL-6 assay in patients with hepatitis C virus. Intervirology 2005 0.76
239 Reduction of opioid side effects by prophylactic measures of palliative care team may result in improved quality of life. J Palliat Med 2010 0.76
240 Effects of Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) on intestinal function in streptozotocin-induced diabetic rats. Yakugaku Zasshi 2007 0.76
241 Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load. Intern Med 2010 0.76
242 Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection. J Gastroenterol 2006 0.76
243 Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load. Intern Med 2008 0.76
244 [Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure]. Nihon Shokakibyo Gakkai Zasshi 2011 0.76
245 Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load. Hepatol Res 2007 0.76
246 Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection. Dig Dis Sci 2004 0.76
247 Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy. Dig Dis Sci 2002 0.75
248 High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load. J Gastroenterol 2004 0.75
249 Significance of oral glucose tolerance tests in non-alcoholic fatty liver disease patients with a fasting plasma glucose level of <126 mg/dL and HbA1c level of ≤ 6.4% in Japan. Intern Med 2015 0.75
250 New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan. Hepatol Int 2015 0.75
251 Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis. Intervirology 2012 0.75
252 [Case report; Intestinal Behçet's disease in monozygotic twins]. Nihon Naika Gakkai Zasshi 2014 0.75
253 [An autopsy case of 54-year-old man with progressive dementia]. No To Shinkei 2004 0.75
254 Successful control of ruptured hepatocellular carcinoma with radiofrequency ablation. J Gastroenterol 2004 0.75
255 Changes in viral loads of lamivudine-resistant mutants during entecavir therapy. Hepatol Res 2007 0.75
256 Application of terahertz absorption spectroscopy to evaluation of aging variation of medicine. Anal Sci 2011 0.75
257 Assessment of palliative care team activities--survey of medications prescribed immediately before and at the beginning of opioid usage. Yakugaku Zasshi 2008 0.75
258 Subacute speech apraxia and consciousness disturbance in a 57-year-old non-alcoholic man. Neuropathology 2003 0.75
259 [Case report; Fanconi's syndrome and hypophosphatemic osteomalacia associated with adefovir dipivoxil: a case report]. Nihon Naika Gakkai Zasshi 2014 0.75
260 Three-Dimensional Imaging Using Contrast-Enhanced and Three-Dimensional Ultrasound Techniques in the Ablative Zone Treated with a Multipolar Radiofrequency Ablation System for Hepatocellular Carcinoma. Oncology 2016 0.75
261 HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B. J Med Virol 2003 0.75
262 Long-term follow-up of HBeAg-positive young adult Japanese patients treated with corticosteroid withdrawal therapy for chronic hepatitis B. Intervirology 2006 0.75
263 [An autopsy case of senile dementia with pathological features of Parkinson's disease]. No To Shinkei 2004 0.75
264 [A questionnaire survey for pharmacists participating in a home medical care training workshop]. Gan To Kagaku Ryoho 2012 0.75
265 Potential impact of joint association of alanine aminotransferase and gamma-glutamyltransferase on insulin resistance in Japan: The Toranomon Hospital Health Management Center Study 19 (TOPICS 19). Hepatol Res 2014 0.75
266 Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma. Hepatol Res 2013 0.75
267 Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels. Scand J Gastroenterol 2009 0.75
268 Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease. Oncology 2017 0.75
269 Clinicopathological improvement of non-alcoholic steatohepatitis associated with weight loss during a 14-year follow-up period. Liver Int 2007 0.75
270 [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy]. Gan To Kagaku Ryoho 2007 0.75
271 Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin. Intern Med 2007 0.75
272 [Organic cause of emotional depression]. Seishin Shinkeigaku Zasshi 2007 0.75
273 [Predisposition to emotional disorders]. Seishin Shinkeigaku Zasshi 2007 0.75
274 Terahertz absorption spectra of original and generic ceftazidime. Anal Sci 2009 0.75
275 Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study. J Med Virol 2005 0.75
276 Pick's disease with Pick bodies: an unusual autopsy case showing degeneration of the pontine nucleus, dentate nucleus, Clarke's column, and lower motor neuron. Neuropathology 2007 0.75
277 Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies. Dig Dis Sci 2003 0.75
278 Changes of intestinal mucosal and plasma PYY in a diarrhea model rat and influence of loperamide as the treatment agent for diarrhea. Yakugaku Zasshi 2008 0.75
279 Lipiodol and dye at the site of ablation decreases during RFA. Intervirology 2009 0.75
280 Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. Intervirology 2004 0.75
281 Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 2003 0.75
282 Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy. J Med Virol 2012 0.75
283 Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment. J Gastroenterol 2004 0.75
284 Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. J Med Virol 2015 0.75
285 [Anti-viral therapy of type B chronic hepatitis. 1. Selection of evidence-based therapeutic policy]. Nihon Naika Gakkai Zasshi 2008 0.75
286 The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load. Intervirology 2008 0.75
287 New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle. Liver Int 2007 0.75
288 Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B. J Med Virol 2007 0.75
289 [An autopsy case of argyrophilic grain dementia with abundant neurofibrillary tangles]. No To Shinkei 2003 0.75